Advertisement
Singapore markets close in 2 hours 41 minutes

  • Straits Times Index

    3,450.94
    +9.17 (+0.27%)
     

  • Nikkei

    39,153.51
    +627.56 (+1.63%)
     

  • Hang Seng

    17,351.85
    +348.94 (+2.05%)
     

  • FTSE 100

    8,274.41
    -17.94 (-0.22%)
     

  • Bitcoin USD

    66,367.45
    -213.24 (-0.32%)
     

  • CMC Crypto 200

    1,351.82
    +1.71 (+0.13%)
     

  • S&P 500

    5,436.44
    -27.10 (-0.50%)
     

  • Dow

    40,743.33
    +203.40 (+0.50%)
     

  • Nasdaq

    17,147.42
    -222.79 (-1.28%)
     

  • Gold

    2,462.80
    +10.90 (+0.44%)
     

  • Crude Oil

    76.08
    +1.35 (+1.81%)
     

  • 10-Yr Bond

    4.1430
    -0.0350 (-0.84%)
     

  • FTSE Bursa Malaysia

    1,618.69
    +6.75 (+0.42%)
     

  • Jakarta Composite Index

    7,254.45
    +12.59 (+0.17%)
     

  • PSE Index

    6,612.07
    +5.71 (+0.09%)
     

California Nanotechnologies First Quarter 2025 Earnings: EPS: US$0.016 (vs US$0.001 in 1Q 2024)

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

California Nanotechnologies (CVE:CNO) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$1.75m (up 243% from 1Q 2024).

  • Net income: US$696.0k (up by US$660.6k from 1Q 2024).

  • Profit margin: 40% (up from 7.0% in 1Q 2024). The increase in margin was driven by higher revenue.

  • EPS: US$0.016 (up from US$0.001 in 1Q 2024).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

California Nanotechnologies shares are up 84% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 5 warning signs for California Nanotechnologies (of which 2 are significant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com